Biotech Week back issues from September 2003:
Preliminary results of phase III PRIMO-CABG trial reported.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Alexion Pharmaceuticals, Inc., (ALXN) announced preliminary results of its phase III study in a large, multinational trial consisting of more than 3,000 patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass, a ...
Hepatitis vaccines: Recent advances.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- According to recent research published in the International Journal for Parasitology, "Despite the availability of hepatitis A vaccines that might provide protection for decades, hepatitis B vaccines that provides protection for at least 15 years ...
Trial tests treatment for postmenopausal cancer patients who relapse.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- AstraZeneca announced that patient recruitment has begun on an important new trial involving its novel estrogen receptor antagonist, "Faslodex" (fulvestrant). The trial, called EFECT, is designed to answer one of the most important ...
FDA gives green light to U.S. phase I clinical trials for Psoraxine.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Astralis, Ltd., (ASTR) announced that the U.S. Food and Drug Administration (FDA) has allowed the company to start phase I clinical trials in the U.S. for Psoraxine for the treatment of moderate to severe plaque psoriasis. The trial, a ...
Clinical trial: Squalamine improves vision in wet AMD.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Genaera Corp. (GENR) announced strong clinical results, including improved vision, for the phase I/II clinical trial of its systemically administered antiangiogenic drug, squalamine, for the treatment of choroidal neovascularization associated with ...
Labeling changes required for drug products that contain salmeterol.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) is announcing the addition of new safety information and warnings to the labeling for drug products that contain salmeterol, a long-acting bronchodilator used to treat asthma and chronic obstructive ...
Allosteric activators of glucokinase show promise for diabetes therapy.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Allosteric activators of glucokinase show promise as treatments for diabetes. "Glucokinase (GK) plays a key role in whole-body glucose homeostasis by catalyzing the phosphorylation of glucose in cells that express this enzyme, such as ...
Interleukin-21 gene therapy activates perforin-dependent tumor immunity.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Interleukin-21 gene therapy activates perforin-dependent tumor immunity. According to recent research from the United States, "Interleukin (IL)-21 is a key factor in the transition between innate and adaptive immune responses. We have ...
APF112 phase II submitted for FDA review; royalty income increases 11%.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- A.P. Pharma, Inc., (APPA) reported financial results for the 3 months ended June 30, 2003, reflecting increased royalty income and contract revenues as well as higher research and development expenses as the company prepares to initiate a phase II ...
Report tells older Americans how to fight sleeplessness.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- The sleeplessness affecting about one-third of all older Americans is not a natural part of aging and can lead to serious health disorders, according to Getting Your ZZZZZZZs: How Sleep Affects Health and Aging, a new publication from the ...
Heart valve company raises $12.3M in private placement of common stock.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Michael D. Dale, president and CEO of ATS Medical, Inc., (ATSI) announced the execution of agreements to sell 4.4 million shares of common stock for gross proceeds of $12.3 million in a private placement to institutional investors through its ...
Clinical trial cleared for NeuGene against virus; financial results reported.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- AVI BioPharma, Inc., (AVII, AVIIW, AVIIZ) announced that it has satisfied all regulatory requirements for initiating a multicenter phase Ib clinical trial with its NeuGene drug AVI-4020 in patients hospitalized with West Nile virus (WNV). The ...
Blue Cross unit decides to fully cover drug that prolongs patient survival.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- A South Carolina Medicare claims company has decided to pay more for a drug that helps dialysis patients live longer. The change is effective immediately. A recent New England Journal of Medicine study showed patients taking Zemplar had ...
Research alliance centers on monoclonal antibody for inflammatory disease.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories and LigoCyte Pharmaceuticals, Inc., announced a research collaboration on an anti-inflammatory monoclonal antibody for the treatment of inflammatory diseases. The collaboration will employ an antibody developed and ...
Phase I clinical testing of ACP-103 complete.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Acadia Pharmaceuticals has successfully completed phase I clinical testing of ACP-103, the company's proprietary small molecule 5-HT2A inverse agonist. The study was designed to evaluate the safety, tolerability, and pharmacokinetics of ...
Series B financing raises $26.4M to fund infectious disease program.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- ActivBiotics, Inc., announced an initial closing of $26.4 million on its Series B round of financing. MDS Capital Corp. led the funding round that included other new investors BioVentures Investors, F. Hoffmann-LaRoche, Ltd., China ...
Alliance to deliver electronic clinical trial solution.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Acumen Healthcare Solutions, LLC, said the company has partnered with Agiliti, Inc. By providing a robust, centralized information technology infrastructure, Agiliti enables Acumen to provide customers with an affordable, scalable and ...
Biotech company reports $0.36 per share loss.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Adolor Corporation (ADLR) reported financial results for the 3- and 6-month periods ended June 30, 2003. For the 3 months ended June 30, 2003, the company reported a net loss of $11.5 million or $0.36 per basic and diluted share, ...
Patent pending for antibodies to treat solid organ, cell transplant rejection.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Advanced Biotherapy, Inc., (ADVB) announced that it has a patent application pending for the use of antibodies to gamma interferon (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and both antibodies combined for the treatment of solid organ ...
Pulsatile drug company files with SEC for IPO.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Advancis Pharmaceutical Corporation announced that it filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of its common stock. The managing underwriters for the ...
BlockAide trial to begin in fourth quarter; scientific advisory board formed.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (AVRX) announced the formation of its new scientific advisory board, consisting of three well-known academic experts in the areas of anticancer and antiviral development. The company appointed Edward Chu, ...
Oncology drug maker reports 66% increase in revenue.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Aeterna Laboratories, Inc., (AEL; AELA) reported total revenues for the second quarter ended June 30, 2003, of $38.9 million, an increase of 66% compared with total revenues of $23.4 million for the 2002 second quarter. During the second ...
New method available for detecting toxic mold.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Atlanta, Georgia-based indoor air quality company, Air Quality Sciences, Inc., (AQS), is offering a new analysis to test for Stachybotrys chartarum, often referred to as toxic mold, in a fungal sample. AQS is now proposing the use of ...
Dialysis company reports net loss of $0.19 per share.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Aksys, Ltd., (AKSY) reported results for the quarter ended June 30, 2003. For the second quarter of 2003, Aksys reported total revenues of $301,000 compared to no revenue for the second quarter of 2002. Product revenues for the quarter ...
Nasal vaccine may increase protection.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- A vaccine administered through the nasal passages may increase protection against pneumococcal disease compared to the current vaccine, say researchers from Albany Medical College in New York and the University of Alabama at Birmingham. ...
Grants to fund rapid, portable detection systems for HIV, blood lead.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Alderon Biosciences of Research Triangle Park, North Carolina, announced the award of two new research grants. As the original developer and manufacturer of the LeadCare, a U.S. Food and Drug Administration (FDA) approved portable ...
Causes of lower-extremity bowing must be distinguished for proper management.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Causes of lower-extremity bowing must be distinguished for proper management. According to recent research from the United States, "lower-extremity bowing is common in infants and children and can result from a variety of conditions. At ...
Drug delivery company reports $0.47 per share loss.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Alkermes, Inc., (ALKS) reported its financial results for the 3-month period ended June 30, 2003. The net loss on a GAAP basis for the quarter ended June 30, 2003, was $30.6 million or $0.47 per share as compared to a net loss of $45.3 ...
Novel genetic hemophilia markers improve prenatal diagnosis.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- A series of novel genetic markers may improve prenatal hemophilia development. "The heterogeneous nature of the mutations, the size, and the complexity of the factor VIII gene makes direct mutation analysis in hemophilia A families in ...
First component of rolling NDA submitted for RSR13.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that it has begun submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the company's investigational radiation sensitizer, RSR13 (efaproxiral), for the treatment of ...
First Flexogan order delivered to Canadian retailer.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- AlphaRx, Inc., (ALRX) announced their first product delivery. Flexogan, AlphaRx's topical pain reliever, has been delivered to Loblaw Companies Limited, a mass market retailer in Canada. Flexogan, independently tested to be 300% more ...
Study finds limited benefit from two oral drugs.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- An 18-month pilot study of two commonly available treatments has shown no significant benefit in patients with interstitial cystitis (IC). The results are reported in the September 2003 issue of the Journal of Urology. The ...
Breast, prostate cancers focus of new Cancer Society research professorships.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- The American Cancer Society has awarded its latest clinical research professorships to two scientists who are studying the translation of basic biology to the treatment of cancer. The two researchers are Harvard cancer epidemiologist ...
Disaster relief fund in jeopardy.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Over the past year, the American Red Cross spent $114.3 million from its Disaster Relief Fund to provide assistance to victims of more than 3,300 disasters throughout the United States and its territories. Donations, however, totaled ...
Stroke group announces new program in Dallas.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- The American Stroke Association, a division of the American Heart Association, and the Dallas County Medical Society announced the Dallas Area Stroke Network, a voluntary collaboration between hospitals and the Dallas Emergency Medical Service ...
First of three phase III exenatide studies achieves positive results.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., (AMLN) and Eli Lilly and Co. (LLY) announced that exenatide (synthetic exendin-4) produced statistically significant, dose-dependent reductions in the primary glucose control endpoint in a 7-month phase III pivotal ...
Biotherapeutics company reports loss of $0.24 per share.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Applied Molecular Evolution, Inc., (AME, AMEV) reported financial results for the second quarter of 2003. For the quarter ended June 30, 2003, the company reported a net loss of $5.0 million or ($0.24) per share, compared to a net loss ...
Drug discovery firm meets analysts' estimate for revenues, earnings.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) reported financial results for the fourth quarter and full year of fiscal 2003, ended June 30, 2003. During the fourth quarter of fiscal 2003, Array reported total revenue of $7.1 million, compared to $10.0 ...
Device company reports 129% increase in net income.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Arrhythmia Research Technology, Inc., (HRT) and it's wholly owned subsidiary Micron Products, Inc., (Micron) reported total revenue of $1,940,000 and net income of $285,000 for the second quarter of 2003 compared to total revenue of $1,832,000 and ...
Factors influencing choice of prenatal genetic screening by Israeli women identified.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Factors influencing Israeli women's decisions to undergo prenatal genetic screening have been identified. "The number of prenatal genetic tests that are being offered to women is constantly increasing," scientists in Israel noted. ...
FDA approves new therapy.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has approved Crestor (rosuvastatin) to lower cholesterol. Rosuvastatin is in the class of drugs called HMG-CoA reductase inhibitors, also known as statins. These drugs work by partially ...
Ximelagatran is safe given twice daily in a fixed dose regimen.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Ximelagatran is safe given twice daily in a fixed dose regimen. "Ximelagatran (Exanta, AstraZeneca) is a novel, oral direct thrombin inhibitor (oral DTI) that is rapidly converted to melagatran, its active form, following absorption," ...
HIV-1-infected children have impaired immunological memory.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- HIV-infected children who were immunized with "Haemophilus influenzae vaccine exhibited impaired immunological memory. According to a study from Greece, "Haemophilus influenzae type b (Hib) conjugate vaccine-induced immunological memory ...
Patient enrollment completed in phase IIb CART-2 study with AGI-1067.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- AtheroGenics, Inc., (AGIX) has recently completed enrollment in a phase IIb clinical trial evaluating its proprietary v-protectant drug candidate, AGI-1067, as a treatment for atherosclerosis and post-angioplasty restenosis. This ...
Doctors Laboratory to offer VAP expanded cholesterol test.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Doctors Laboratory, Inc., will offer the next-generation VAP (Vertical Auto Profile) Cholesterol Test as part of its expansive menu of diagnostic services. The VAP Test, developed by Birmingham, Alabama-based Atherotech, will be ...
Pharmaceutical company reports net loss of $0.01 per share.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- AutoImmune, Inc., (AIMM) reported a net loss of $0.14 million, or $0.01 per share basic and diluted, for the 3 months ended June 30, 2003, compared with a net loss of $0.18 million, or $0.01 per share basic and diluted, for the 3 months ended June ...
Agreement signed for use of chemical assay.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Avitar, Inc., (AVR) announced that it has signed a Letter of Understanding with Immunomatrix, Inc., for the exclusive right to utilize Immunomatrix's high sensitivity chemical assay technologies in Avitar's rapid, oral fluid drugs-of-abuse ...
FDA approves Photofrin for the ablation of high-grade dysplasia.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., announced that it has received approval from the U.S Food and Drug Administration (FDA) for the use of Photofrin photodynamic therapy (PDT) in the ablation of high-grade dysplasia (HGD) in Barrett esophagus patients who do not ...
Thalidomide has been found to be effective for relapsed or refractory myeloma.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Thalidomide has been found to be effective for relapsed or refractory myeloma. "Since new treatments have recently been proposed for patients with multiple myeloma, the aim of this article is to review the main innovations in this ...
Company's system helps reduce medication errors.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- B. Braun Medical, Inc., announced the launch of a new high speed production line in Irvine, California, to meet the growing customer demand for the Duplex Drug Delivery System, a new system designed to simplify intravenous antibiotic delivery to ...
Pharmaceutical firm reports earnings of $2.43 per share.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) reported revenues of $902.9 million and net earnings of $167.6 million, or $2.43 per fully diluted share for its fiscal year ended June 30, 2003, which included charges of $0.22 per fully diluted share for legal fees ...
Inactivated parapoxvirus ovis protects against hepatitis and herpes viruses.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Inactivated parapoxvirus ovis protects against hepatitis and herpes viruses. "It is known that some viruses are able to induce vigorous immune reactions. This study shows that inactivated parapoxvirus ovis (Orf virus), strain D1701 ...
Targeted DNA vaccine may reverse disease.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Stanford University Medical Center researchers have developed a way to tailor therapies to combat the specific inappropriate responses of autoimmune diseases in mice. The researchers also have shown that their technique can provide information ...
Hepatitis C virus patients often form elevated serum lipase levels.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Hepatitis C virus patients often form elevated serum lipase levels. "Extrahepatic manifestations of chronic hepatitis C virus (HCV) infection have been well described. However, hyperlipasemia and/or pancreatitis have not been reported ....
Novel HIV-based cDNA cloning system may aid genetic research.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- A novel HIV-based cDNA cloning system may aid genetic research. "Expression cloning of cDNAs is a powerful tool with which to identify genes based on their specific functional properties," scientists in Texas explained. M ....
Substance P expression linked to diarrhea severity during cryptosporidiosis.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Substance P (SP) expression is linked to diarrhea severity in cryptosporidiosis patients. "Cryptosporidiosis, caused by Cryptosporidium parvum, is self-limited in immunocompetent hosts but may cause chronic diarrhea in patients with ...
InnaPhase finalizes acquisition of laboratory automation operations.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- InnaPhase Corp., a privately owned software company and provider of laboratory information management systems (LIMS) solutions for the life-sciences market, announced that it has closed the transaction with Beckman Coulter, Inc., Fullerton, ...
Drug information available in handheld database.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Beiks LLC has released the MedicineNet Pocket Drug Guide, a new handheld version of MedicineNet, Inc.'s doctor-produced informational database of 400-plus monographs covering more than 1,000 generic and branded names of the most popular U.S ....
User-defined assays may have applicability in management of leukemia.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- User-defined assays may have applicability in management of leukemia. "An increasing number of risk-stratifying genetic lesions in acute leukemia are being discovered and characterized," scientists in the United States report. ...
FDA license granted for new HIV test kit.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Bio-Rad Laboratories, Inc., (BIO, BIO.B) has received a license from the U.S. Food and Drug Administration for its HIV-1/HIV-2 PLUS O EIA test kit used for diagnostic testing and the screening of blood and blood products. The test ...
Pharmaceutical firm reports loss of $0.14 per share.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- BioMarin Pharmaceutical, Inc., (BMRN) announced financial results for its second quarter ended June 30, 2003. The net loss was $9.1 million ($0.14 per share) for the second quarter of 2003 compared to $14.4 million ($0.27 per share) for ...
Hormone therapy company raises $10.3M in private placement.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that it has raised $10.3 million through the private placement of approximately 4.8 million newly issued shares of BioSante common stock to several new and current institutional and accredited ...
Biotech firm reports conditional continued listing on NASDAQ SmallCap.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- BioSpecifics Technologies Corp. (BSTCE) has been notified by The NASDAQ Stock Market that the NASDAQ Listing Qualifications Panel has determined to continue the listing of the company's common stock on The NASDAQ SmallCap Market pursuant to the ...
Status of stock offering reported by laser company.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Biolase Technology, Inc., (BLTI) announced that it and its independent accountants have decided to seek guidance from the U.S. Securities and Exchange Commission (SEC) regarding the accounting affect of certain language in the company's purchase ...
RABBIT trial started to evaluate b-type natriuretic peptide.
Sep 03, 2003 ... 2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Biosite Incorporated (BSTE) announced the start of the RABBIT (Rapid Assessment of Bedside BNP in Treatment of congestive heart failure) clinical trial, which is designed to evaluate measurements of b-type natriuretic peptide (BNP) in outpatients ...